A phase 1b/2a multi-center, dose escalation and reference regimen-controlled, multi-cohort study to determine the safety and efficacy of oral 7HP349 (Alintegimod) in combination with Ipilimumab followed by Nivolumab Monotherapy in patients with locally advanced or metastatic cancers following one or more prior therapies

Disease:

Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations

Study phase:

Physician name:

Apostolia Tsimberidou

Department:

Investigational Cancer Therapeutics

For general questions about clinical trials:

1-866-379-1063